This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk07: reflected within restricted cash on our balance sheet due to specific use requirements in that agreement. We closed the year with $48.9 billion in unrestricted cash and cash equivalents and $22.2 million in restricted cash related to adjuvant. Now, to remind everyone, our revenue recognition is based on unit shipments from our warehouse to distributors. In Q3, those shipments were the initial stocking orders for the FEXI launch. Q4 shipments were lower, with reorders coming mainly toward the end of the quarter to replenish inventory that was depleted by increasing shipments from the distributors to retail pharmacies during the quarter. As expected, unit shipments in Q1 2021 are on track to exceed total unit shipments last year. We believe this reflects increased market demand even before the GetFexy DTC campaign launched. and gives us confidence that gross revenues are moving firmly in the right direction for the current quarter. Also, I want to point out that we closed 2020 with approximately six months of inventory on hand, and we have ample manufacturing capacity to meet anticipated demand for the foreseeable future, including the expected impact of the GetFexy campaign. With that, I'll turn it back to Sandra.
spk08: Thanks, Jay. There are moments in time when categories change, when the culture, and the climate of a given standard changes forever because it is no longer suitable. The time for women to have to take a hormone every single day when they don't have sex every day is, quite frankly, over. More importantly, the solution puts control in the hands of women. Men have had the option to have sex on demand safely for years, but women have not had that same freedom or access to an FDA-approved on-demand method with no hormones. That's what makes this time right for sexy. There are 21 million women in the U.S. that are at risk for pregnancy who are not using hormonal birth control. They have demonstrated through their actions that they are not going to take hormones. Some women are using non-prescription contraception, such as barrier methods, withdrawal, or periodic abstinence. Others are using no contraception at all, despite the fact that they have an 85% relative risk of getting pregnant within one year if they continue to have unprotected sex. We believe that a very conservative acquisition percentage of these 21 million women makes this potentially a billion-dollar opportunity. And in addition to these 21 million women, there's another 19 million currently using a prescription contraceptive, some of whom, particularly pill users, may already be considering moving to a hormone-free, on-demand method. Factoring conservative levels of uptake from this segment as well, we believe that Sexy's peak revenue potential could be as high as $1.4 billion to $2.3 billion. And again, this is based on only single-digit acquisition percentages of women in each of these groups. Sexy sales from wholesalers to pharmacies have established a very strong growth trend since launch. On average, we've seen greater than 20% unit growth in the last three months. This is the best leading indicator of demand. And I want to point out, February was a short month, hampered by weather events across the country that shut down several states. But despite that, it was our strongest sales volume month to date. We reached a new high for weekly sales the last week in February following the launch of the Get Sexy ad on television. Pepsi prescriptions continue to grow despite COVID-19, despite the holidays and the recent polar vortex. Since the Pepsi launch in September of last year, our marketing efforts have been growing and setting a strong foundation with a strong footprint with consumers. But it was crucial that we escalate those efforts to ensure that we drive the mass reach needed to break through. In 2021, our focus and goal is to rapidly increase awareness and to drive demand. In doing this, we'll bring more women to the top of the funnel, then actively work to move them through the funnel all the way to conversion. We estimate every 1% increase in sexy awareness translates to approximately $30 million in gross revenue. As of today, we have IQVIA data through the week ending February 12th. Total sexy prescriptions hit new weekly highs in each of the first two weeks of the month. leading into the launch of our DTC campaign on Valentine's Day, which we anticipate will have a very significant impact on the SEXI growth curve. As you know, we launched SEXI in September of 2020, and we launched it with a hybrid commercial team. We have 59 FOSM representatives in the field, working with 11 regional managers and calling on roughly the top 3,500 accounts and 10,000 healthcare provider targets. They're complemented by a telesales team contracted with Archer Healthcare that we're using to reach HCP targets in remote geographies or where in-person access has been rendered impossible during the COVID lockdown. Both our EvoFem and Archer reps are focusing specifically on healthcare providers who are likely to write sexy based on their contraceptive prescribing history and attitudinal segmentation. I am very pleased to say that our well-trained, focused, and committed sales organization continues to deliver impressive results. As of February 12th, more than 2,650 healthcare providers have prescribed FEXI. Jay and I both mentioned the Get FEXI campaign and its impact already several times, but I want to take a step back. I want to make sure that you understand what we're referring to exactly. This high-impact, dynamic campaign is designed to reach women in a purposeful and a targeted manner. It encompasses television, streaming, and digital channels, and leverages influencers and partnerships with the ultimate goal of driving demand for fexes. The GetFexy ad highlights some of the struggles that women face when they choose among the many available methods of contraception, whether it's the lack of control of condoms, constant daily use of the pill, or abstinence required for cycle tracking. the women featured in the commercial represent real-life drawbacks that FEXI can help eliminate as a hormone-free, on-demand birth control method. In just the first two weeks after GetFEXI launched, our ads generated 115 million views and impressions across all media channels. FEXI brand awareness doubled from January. To put this in perspective, we were tracking at about 4% and it was literally like flipping a switch. We went, boom, immediately to 8% in one month. Organic searches for Sexy have increased 362% since launch, and direct web traffic, meaning people typing in Sexy.com in their browsers, is up 200%. Actions on Sexy.com have also increased dramatically. telehealth booking and fulfillment by our third party mail order pharmacy reached new weekly highs for both weeks ending February 19th and February 26th. For the week ending February 26th, over 300 telehealth appointments were booked and 100% of those were completed and Sexy was prescribed and dispensed to 100% of these women. And again, we're not even really seeing the impact of the Get Sexy DTC campaign on prescribers or total prescriptions yet because we only had data through February 12th. So stay tuned. Another initiative we expect that will positively impact Sexy Uptake is our collaboration with ENCODA. Our collective goal is to support female cancer patients as they decide which contraceptive option best meets their unique individual needs. There are more than 800,000 new cases of cancer reported in women in the U.S. every single year. Many cancer treatment protocols require female patients of reproductive age to use birth control while they undergo treatment, and the vast majority of oncologists will not permit their patients to use hormonal birth control. If you just look at breast cancer alone, the American Society of Reproductive Medicine recommends that all women who are suspected or known to have breast cancer or who have had it in the past should avoid hormonal contraception. So, if you consider the anticipated impact of the DTC campaign on FEXI uptake, as well as the heightened awareness that we aim to build among oncology pharmacy teams and the patients they serve, we expect the FEXI uptake curve will increase dramatically from where it was in December and January. Market access remains a priority. We're proud to have 55% of commercial lives covered and additional coverage to the Medicaid National Drug Rebate Program that covers 17 million women aged 19 to 49. And already, we have multiple plans with FECSI at zero copay. We continue to offer our copay support program to women whose plans don't yet cover FECSI or that have it on formulary with a copay of over $30 for FECSI, because access is our near-term priority. Meanwhile, we're working diligently through multiple channels to achieve our goal of affordable access to Sexy for all women. This includes advocating for the Office of Women's Health to update and expand its contraceptive categories to include a new category, vaginal pH modulator, to reflect Sexy's unique mechanism of action. We believe this mandate will increase coverage for women of reproductive age under ACA. contraceptive choice should not be a luxury available just to some women. Every woman deserves to choose the method that's right for her individual health and her unique circumstances. So now I quickly want to pivot and just talk to you briefly about our STI prevention program. Our next asset in development is EVO 100 for the prevention of the two most common STIs, chlamydia and gonorrhea. This is a late-stage program and a near-term opportunity And STI prevention is another potentially large market with a clear unmet medical need. STI prevention is critically important now more than ever because rates of chlamydia and gonorrhea have climbed in 2018 for the fifth consecutive year in a row in the United States with 1.8 million cases of chlamydia and 600,000 of gonorrhea. But here's why it matters. Many STIs are asymptomatic. They go undiagnosed. They go untreated, and that's very problematic for two reasons. One, there are serious health consequences for infected people. If it's left untreated, some infections will cause pelvic inflammatory disease, infertility, or severe complications in pregnancy and for newborns. And the infected person can unknowingly infect sexual partners. That's why the CDC says, Anyone who's sexually active can get gonorrhea or chlamydia. And in the U.S. alone, there are 78 million sexually active women, and they are all potentially at risk for STIs. So in October, we initiated our pivotal phase three trial for EVO 100. This trial will enroll 1,730 women at 90 U.S. study sites, and 59 of these sites have already been activated. We continue on track to complete our enrollment by the end of this year, and we expect to report top line results in the first half of 2022. This will keep us on schedule to file the NDA for these potential indications by the end of next year. And again, I want to say it again, there are 78 million women at risk for these STIs in the U.S. alone. So we believe this makes this a significant market opportunity. So I'd like to end with the word that I started with, execution. Yes, the pandemic is making our efforts challenging, but I want to assure you that we are an organization that continues to find solutions to create access to FEXI no matter what. We're just getting started. And if you have any doubt about whether this is the right time for FEXI, I want to remind you, in just two weeks of our Get FEXI campaign, The search for FEXI is up 362%. So with that, I'd like to open the call for questions.
spk09: Thank you. As a reminder, to ask a question, you would need to press star then 1 on your telephone. To withdraw your question, please press the pound key. Our first question comes from the line of Jeff Hung with Morgan Stanley. Your line is now open.
spk04: Thanks for taking the questions. What was the average price per script in fourth quarter, and how do you view that changing over the course of 2021 as it relates to the DTC campaign and the dynamics and duration of the COFI assistance program? And then I can follow up.
spk08: No, thank you, Jeff, for the question. Jay, I'm going to have our CFO, Jay Feil, address that.
spk07: Sure, thanks. Good to hear you, Jeff. Yeah, no, great question. And, you know, you obviously heard Sandra and I talk rather extensively about how significant the co-pay program is for us at launch, all the way through, obviously, building upon the DTC campaign. So with that, obviously, we've got a high GTN adjustment, at least through the end of the year. Now, ultimately, we do anticipate that That is ultimately a moving target for us, and it's going to continue to shift depending on the ultimate mix of usage over time. And we do, though, expect that to improve as the year progresses and into 2022. So right now, if you just do it straight off the fund answers I've presented, it was about an 80% adjustment. I'll do the math for you. Does that give you a little bit of clarity that you're hoping for?
spk04: Yeah, that's helpful. Thank you. And then I guess with regards to the ENCODA collaboration, what proportion of the 800,000 new cases of cancer reported amongst women are of childbearing age? And are there specific subgroups within these women that you think are easier to reach first? Thanks.
spk08: Yeah. So basically, out of the 800,000, it's about 60% are childbearing age, and to be candid, It really is that 60% that we think are the main target. Because right now, at the end of the day, before FEXE was approved, the only other product that these oncologists had access to was a copper IUD. And in my own experience, being a cancer conqueror, I don't say survivor, I say conqueror, but a lot of oncologists, You know, after women have gone through treatment and they have suffered enough, the oncologists are very mindful to make sure that they want to give women something that they can tolerate. And a lot of women have had a lot of serious side effects with copper IUDs. And so, frankly, when our product got to market, a whole oncology team that I spoke to myself personally said it's almost like you designed this, you know, for cancer patients in mind. Now, certainly... these women are on top of these 21 million that we talk about that currently are not using hormones. And these are the women on top of what we believe are pill users who are looking for something different. But we really believe this is a low-hanging fruit. And the one thing I want to say is that being a cancer patient myself, I feel like I can speak to this audience in a way that's different, that's authentic. And The final thing I want to say is that one of the oncologists I spoke to, and we had this in the script, but I was encouraged to take it out. But now that you asked, Jeff, thank you, by the way, I can say it, is that the oncologist said to me, look, when men are in treatment for prostate cancer, the number one thing they ask is, will they still be able to get an erection? And can you imagine if a woman in cancer treatment started talking about her sexualities? Can you imagine if she started talking about her orgasms, what we would think of her? So there's still inequities even in cancer patients. The reality is that these women have so much vaginal dryness. They have bleeding. They have pain with intercourse. So the lubricating properties of sexy make it so advantageous for these patients. So I'm really proud. This is a bit of a passion project for me, but I'm very, very proud that these women need an option and they they're still seeing their doctor no matter what. Believe me, when you're in cancer treatment, it doesn't matter what's happening in the world. You're still going to your doctor. And so we are very excited that this is a bit of a low-hanging fruit that will add a lot of value to women, by the way, but I think it will also really deliver in the growth of access and our prescriptions.
spk04: Thanks so much, Margaret.
spk08: Yeah, thanks, Jeff. Thank you.
spk09: Thank you. Our next question comes from the line of Annabelle Chamomille with Staple. Your line is now open.
spk01: Hi, all. Thanks for taking my question. I had a few, and I guess the first one is to what extent, for those patients who have started, are you able to convert these patients into repeat users? Do you have any kind of refill rate at this point? Are you on track with your expected per patient prescriptions per year? And then I guess this somewhat goes hand in hand with the next question, but if you could give us a little bit more granularity on payer adoption, it looks like it's still at 55%. What are your expectations for payer adoption going forward? And if there's any sense of what percent are unrestricted versus restricted, and, you know, open access, preferred, non-preferred, and how might that play into the gross net at this point. So it's a little bit loaded, but I'll continue. I'll follow up later. No, no, no.
spk08: Thank you, Annabelle. That's great. So, Russ, could I get you to start, if you don't mind, and talk about the refills and the patients and the conversion, and then we'll circle back to the payer questions?
spk05: Happy to do so. One of the things that we are so excited about is that we were able to do a small research project with 127 women who had completed their first full month of SEXI. And the questions we asked them that are relevant to this question were specifically, is your intention to continue to use SEXI? What's your intention around SEXI? recommended it to a friend, et cetera. So we saw 89%, which is right about almost what we saw coming out of the clinical trial, where it was about 90% that said that they were intending on using FEXE as they continued to move. But this is nice because it's real-world data, of course. And 82%, which is a very similar number to what we saw, again, with the clinical trial, said that they would recommend it to a friend. Now, one of the things that I have to kind of just caution everyone on in terms of the refill rate is that because FEXI is an on-demand method that isn't like an oral contraception or a statin or something that you might be on an ongoing basis. We know that the refill rates will be different from woman to woman. And we also know that what happens now that physicians are getting experience with FEXI is they'll, for an example, say to the woman, how often are you sexually active? And if she starts approaching sexual activity of 10 or more times a month, what they will now do is write the prescription that says that the prescription is for 24 applicators, not for 12, and those don't get captured as refills because it's a size difference from the initial 12, one box in that regard. So we're going to need data probably for five or six applications to seven months in order to understand what the real refill rate looks like. So we're really focused now on the units. What are the units that are going forward? and how much are new prescribers coming online, and those kinds of metrics, and those are all really encouraging. So we do believe that the adherence and the continuation is going to be very high for FEXI, but as of yet, we don't have the IQVIA data to really know for sure what that rate looks like.
spk08: And then just to touch on the payer question, So a couple things I want to say. And then we actually have our internal expert, Harry Jordan, who's in charge of all the payer initiatives. He perhaps forgot more about the payer initiatives than most of us will ever know. But I do want to say that, look, 55% coverage of commercial lives is where we are today. And we do have our co-pay program in place so that healthcare providers and patients won't feel cost constraints around prescribing or obtaining PECC-C. I'd like to see, Harry, if you're there, if you could jump in so you could give Annabelle much more crisp insight on, you know, what are our initiatives and steps that we plan to do to increase coverage.
spk06: Absolutely. So thank you, Sandra. And hopefully you can hear me okay. So I think your first question was about where do we expect our payer coverage to go. So we're at 55.1% right now. And as you know, the PBMs, the pharmacy benefit managers, they control roughly about half the lives, the top three PBMs control about half the lives across the US. We currently are working with them. We continue to have communication with them. However, they usually are looking for pretty deep discounts and rebates, especially when you have a new product and you don't have any market share. So our number one goal is to drive demand and market share, and that will give us more leverage as we go into the year. Second to that, when you look at zero cost right now, we roughly have about 4.6% of lives covered under zero dollars, 0.7% under preferred, and between covered new to market and normal coverage, at non-preferred tier is roughly about 49% of those covered lives. So we do have a lot of plans across the U.S. that have made positive coverage decisions in spite of what the PBMs do to try to get more rebates from a new product when it first launches.
spk01: Just on that note, if there's anything installing and adoption by the PBMs, is there any thought to changing the copay assistance or the first prescription copay all the way down to zero to maybe help with the gross net and give you a little bit more juice as you're trying to work on the coverage?
spk06: Yeah, absolutely. So we constantly, that's one of the nice things about a copay assistance program is that we can change the business rules. as we see fit, right? So it's very important that we, the payers see the demand, and so we work through the prior authorizations so they see this demand, but we also don't want to hold up and thwart the demand by holding up the process with PAs. So what we do is we make sure that, number one, that patients get the product, but then we work the prior authorizations on the back end which we're finding out a lot of these prior authorizations are fairly simple and easy to handle.
spk01: Okay. All right, great. I'll follow up later. Thank you.
spk09: Okay. Thanks, Annabelle. Thank you. Our next question comes from the line of David Anselm with Piper Sandler. Your line is now open.
spk02: Thanks. So I just have a couple. So on the payer landscape, can you say what portion of, covered commercial lives have access at zero copay currently? And then in that 55% that you say have access, would you characterize that as hassle-free or is there some utilization management involved that we should be aware of, at least in a meaningful sense, in that 55%? And then lastly, I want to make sure I got all your comments about the 19th pregnancy category, sorry, contraception category straight, but I wanted to make sure I got those, it was clear on that. So do you have sort of a sense of when we're going to hear on that, when we'll definitively know if sexy is going to get, you know, its unique category? Thanks.
spk08: Okay, so, Harry, since you're warmed up and you're on a roll, would you like to start with David's question, and then once we get to the ACA, you and I can handle it in tandem?
spk06: Absolutely. Yes, so thanks, David. Yes, $0 copay right now, roughly about 4.5% of those lives fall under that, roughly about 8.3 million lives across the U.S. that we know plans that have made decisions around it. there's also state laws. There's roughly 12 states that, um, mandate, uh, either $0 copay or, uh, very low copay based on, on the patient. So, and it's hard to track exactly, you know, what, you know, cause you can have a plan that's covering in a non-preferred tier, but because of the state laws, they supersede that. So, um, so that eight, that 4.6% could be more, but there, there's the plans that we're tracking. And, um, I forget your second question around the ACA. I know it's ACA, but you had a question before this.
spk02: Well, it was on utilization management and just on the 55%. Yeah.
spk06: Got it. So we roughly have about 18% of commercial lives that's unrestricted. And there is some restrictions. The restrictions are typically prior authorizations that require it to be used to label. And so, and again, like I mentioned, they're fairly mundane prior authorizations that we work through.
spk08: And then, David, to speak about when we're talking about, you know, ACA and we're talking about the 19th category, and, you know, Harry, please feel free to, you know, add anything. I mean, look, one of the things that we feel is a positive lever for us is vaginal pH modulator and the fact that there is a huge subset of women that are clinically contraindicated for hormones. This isn't just saying, let's just put another product in the armamentarium that's me too, like everybody else and like everything else. We feel that there is serious clinical leverage, that there is a subset of women that do not have a suitable option. So we hired a well-known lobbyist. He has 35 years history working in the healthcare field And he has 28 years' experience lobbying Democrats in Congress and the Democratic administration to help support awareness for fexy. We also have been working with these very large, very serious advocacy groups that are very loud and very influential around making sure that women are prioritized and that they really believe that contraception is an essential tool in preventative health and economic well-being of U.S. women. And I can assure you this. They are completely on the vexing bandwagon. They believe that it has been far too long that women have not had an option like this. So we're working with this lobbyist, we're working with these advocacy groups, and we're actually, you know, working very heavily trying to influence politicians. And I would tell you that it is, I am optimistic about that. So we're encouraged. But here's what I would tell you. COVID has put everything, and And I'm not trying to make an excuse, but COVID has made this less of a priority for everybody. So we've tried to continue to escalate this. We've tried to continue to push on all the doors that we can simultaneously. So I don't know if, Harry, you want to jump in, because David's exact question was, what do you think about timing around this? And I don't know if you have any more clarity than I have about what would be a timing he could expect.
spk06: Yeah, here's what I will say to that. We've gotten some really good responses from some several senators' offices. They understand that the birth control chart is way behind being updated. It hasn't been updated since its inception 10 years ago. And so they are working with us to push the Office of Women's Health to update the chart. As far as timing, you know, that's something that's really out of our control. All we can do is keep the heat on. and keep the pressure on. But our hope is that we would hear something this year and be able to obviously act on it from a payer perspective.
spk02: Okay, that's helpful. Just to be clear, though, you're, you know, in parallel, though, you're working with and having discussions with commercial plans about, you about a zero copay coverage. So can you talk qualitatively how those discussions are going?
spk06: Yeah, absolutely. You know, I think our position is that, you know, FEXI should fall under the mandate and be covered at $0. You can understand that the pharmacy benefit manager will take an opposition to that because they don't want to pay for anything they don't have to. So, you know, we continue to work and educate them about the product or mechanism of action. And we do it in a manner as, you know, we're in front of them as much as we can. We've brought in our chief medical officer with many of those meetings. We recently had a meeting with one of the larger payers in the country. So we continue to have those conversations. Obviously, it's easier if you have a mandate because then they can't fight that. But we continue to have those conversations moving forward. Well, and just to say this, yep, sorry.
spk08: David, just one more thing just to say is that, look, I mean, the tough thing, right, the tough thing is balancing access versus these, look, Harry's too politically correct to say this, but some of these rebates that they are requesting are exorbitant. They are insane rebates. And they want us to sign these contracts for three to five years with these deep discounts that it's just not responsible. It's not a responsible strategy for our shareholders. And so because of that, we have purposely put our heels on the ground to say, well, you just can't do that. So, you know, we don't want to do it to the detriment of women, but what we're trying to do is push on this ACA door as hard as possible because should that come to fruition, by the way, then they're not going to have any choice. Then they're going to have to cover us and we're not going to have to be, you know, held our feet to the fire with these insane rebates. So that's what the tough balance is. It's not that we couldn't get the coverage. It's that we right now just don't think it's prudent and we don't think it's a smart business strategy because, you know, they feel like they're getting these rebates from some players. So they think, well, you either play ball by our rules or forget it. So we're trying the opposite to get this ACA coverage first, and while we're continuing, you know, to try to influence them in every way that we can.
spk02: Okay, thanks, Sandra.
spk08: Yeah, thanks, Jared.
spk09: Thank you. Our last question comes from the line of Ram Sovaraju with HC Wainwright. Your line is now open.
spk03: Hi, thanks very much for taking my questions. Just three pretty quick ones. Firstly, I was wondering if there's likely to be a substantial difference in not only a level of demand, level of interest from both patients as well as prescribers within the cancer patient population, but also whether there's likely to be a substantial difference there with regard to willingness of commercial plans to cover the product or if you don't anticipate there being a significant difference between that subsegment versus the market as a whole. Secondly, I wanted to ask if you had seen any clear indications emerging from among the practitioner group who have already written prescriptions for Phexy regarding what percentage of that group are likely to be definitive repeat prescribers of the product. And then lastly, I wanted to know if you could comment on specifically timing placement of TV ads for Pepsi during the day. What times do these ads typically air? Do you expect that to change over time, especially over the course of the next few? Thank you.
spk08: Great. Thank you so much, Ron. Okay. So, Russ, I'm going to ask you to answer Ron's question around the repeat prescribers and around the timings. of the television ads and when those are placed. And I'm going to just start with the cancer question. Ram, I have to tell you, you have read behind the line, meaning that the short answer is yes. A unbelievably key lever is this cancer population in getting these plans to open up their mindset around coverage. Look, at first, everybody wants to say no. There's just no driven answer. They think the category of contraception is crowded. They think there's tons of generics out there. They, at first, out of the gate, wonder why there's even a new contraceptive product. But once you have the opportunity to not just talk about non-hormonal, but to talk about all of these women, and by the way, not just cancer patients, but there's a huge number of patients that have clinical contraindications, whether their BMI is high, whether they're a smoker. But the cancer patients, because these women are so vulnerable, it has been such an important factor in our ability to influence decision makers. And look, at first, I will be candid, and Russ will tell you this, but at first, the commercial team, you know, they wanted me to go away on a silent vacation. They were like, Sandra, we are not going down the cancer road. And I kept saying, we have to. We have to. And so anyway, finally, I think I wore them down. But in the end, the whole commercial team agrees now that that it has been such a critical piece of the sexy story because, you know, it's just such an important thing to say this is for every woman. And it doesn't matter what your BMI is. It doesn't matter what other medications that you're on, but particularly if you are a cancer patient. So, yes, it's been an important lever getting them to decide quicker and and getting them to not have to be so controversial, right? It's easy. They almost feel like they're becoming the good guys because they're helping these poor cancer patients. And so it's been a very, very important. Now, the layer of your question, which was, are there some times that they're just covering it for cancer patients? The short answer is yes. But we are trying to get those places to really share those stories and the oncologists to have more influence to say, This should be for a variety of different women because, by the way, there's a lot of young women that are worried about their health future. They're worried about, you know, what's going to happen if they use different medications for periods of time, and they should also have access to something non-hormonal. So we are definitely utilizing that to our benefit. That was a long answer. Sorry about that. But, Russ, will you transition to the repeat prescribers in the TV ads?
spk05: Sure. So as we mentioned, we currently have about 2,600-plus HCPs that have written a prescription, and about 40% of those are repeat prescribers. As you start looking at the month's You know, from December, January, February, we start seeing that the numbers continue to be closer to 50% that are writing a second prescription. So as the new prescribers come into the channel, we are seeing them continue to write. We've already seen a couple of prescribers that have written over 100 prescriptions already. So it varies from those who have written few to those that have already adopted this into their armamentarium. And then the other question is on the television and on where they'll see this. And as Sandra already mentioned, this is across all media channels, both cable and over the air in like Hulu and places like that, YouTube TV, as well as on YouTube streaming. And what we've really selected to do is is that we are going out to where our audience is. So majority of those are actually airing in evening hours, but it can start earlier depending on where you're at in the country. But the key that's really interesting is this, is we've got some, eyebrows raised by people who said, why did you go back to cable? Is cable so yesterday? But what we knew was this, is from our research, we had worked with our media placement partner, and they came back and said, because of COVID, we have this return that's going on where people are spending more time, women are spending more time back in some of the traditional channels like and that has proven to be so true already for us as we've just gotten the anecdotal responses from our target audience over and over again saying, Matt, I was just watching this show and here was your ad. So it's primarily evening hours, but it is where our target audience is and it's been resonating with them as Sandra already suggested with well over 350% increase in search for PECSI.
spk03: Just as a clarificatory point there, I was wondering if you could confirm whether or not there are ads for FEXI currently running on streaming platforms or not.
spk05: Yes, there are.
spk03: Thank you.
spk09: Thank you. This concludes today's question and answer session. I will now turn the call back to Sandra Pelletier for closing remarks.
spk08: I just want to thank everybody for taking your time to listen to our update and for joining us. And we really appreciate your ongoing interest. We appreciate your support of women's health. And we look forward to speaking to you soon. And I hope you have a great rest of your day. Bye-bye.
spk09: Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.
Disclaimer